GleamWall
中文EN

PTCT PTC THERAPEUTICS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1070081 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-35.1%
TTM net income YoY-114.1%
TTM EPS YoY-115.5%
Revenue 3-yr CAGR13.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin12.8%
Net margin-9.2%
FCF margin0.2%
EBITDA margin18.1%

Returns

ROE—
ROA-3.6%
ROIC (approx.)—
Asset turnover0.39x

Leverage & solvency

Liabilities / assets106.0%
Debt / equity—
Current ratio3.27x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.10x
Accruals ratio-4.0%
Payout ratio—
Capex / revenue0.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$357.81M$360.52M$272.55M$164.68M$211.01M$178.88M$1.18B$213.17M
R&D expense$105.35M$99.15M$100.87M$133.13M$100.16M$112.99M$108.97M$124.77M
SG&A expense$80.08M$80.63M$86.18M$96.87M$84.05M$85.26M$80.96M$84.68M
Operating income$25.11M$148.98M$44.96M-$71.35M$3.02M-$34.96M$970.23M-$162.39M
Pretax income-$41.09M$97.55M-$2.46M-$139.08M-$23.07M-$71.05M$929.83M-$94.70M
Income tax$10.61M$14.05M$347,000-$4.12M-$38.97M-$6.20M$63.27M-$28.81M
Net income-$51.69M$83.50M-$2.81M-$134.97M$15.90M-$64.85M$866.56M-$65.89M
EBITDA$41.93M$164.85M$60.37M-$58.45M$14.12M-$27.37M$977.45M-$155.62M
EPS (basic)-0.621.01-0.03—0.20-0.8311.09—
EPS (diluted)-0.620.92-0.03—0.20-0.8310.04—
Weighted avg. shares (diluted)83.48M92.02M82.52M—87.12M78.15M86.39M—
Balance sheet
Cash & equivalents$508.89M$1.05B$833.99M$984.65M$686.30M$1.03B$1.50B$795.32M
Short-term investments$1.62B$1.18B$1.06B$960.72M$1.02B$971.76M$546.95M$359.99M
Receivables$238.07M$239.04M$219.92M$181.62M$203.07M$196.13M$210.50M$158.55M
Inventory$109.33M$91.35M$75.57M$79.65M$52.69M$34.06M$21.68M$23.19M
Current assets$2.54B$2.62B$2.25B$2.27B$2.01B$2.27B$2.32B$1.37B
PP&E, net$49.33M$51.49M$52.74M$55.37M$56.97M$57.19M$59.46M$60.97M
Goodwill$82.34M$82.34M$82.34M$82.34M$82.34M$82.34M$82.34M$82.34M
Intangibles$443.69M$402.93M$380.68M$388.75M$396.47M$143.81M$118.45M$118.79M
Total assets$3.21B$3.25B$2.87B$2.90B$2.64B$2.63B$2.66B$1.71B
Current liabilities$776.08M$771.07M$923.60M$968.43M$866.25M$627.81M$595.39M$580.98M
Short-term debt—$55.45M$286.94M$286.63M$286.32M———
Long-term debt$536.27M$535.52M———$286.01M$285.71M$285.41M
Total debt$536.27M$590.97M———$286.01M$285.71M$285.41M
Total liabilities$3.40B$3.42B$3.05B$3.10B$2.80B$2.84B$2.84B$2.80B
Shareholders' equity-$191.21M-$165.36M-$180.47M-$205.31M-$155.76M-$206.55M-$185.76M-$1.10B
Net debt$27.37M-$458.92M———-$747.06M-$1.21B-$509.90M
Shares outstanding83.54M83.33M82.88M81.47M79.93M79.38M79.23M77.70M
Cash flow statement
Operating cash flow-$25.31M$129.11M-$59.04M-$34.27M-$66.30M-$58.33M$870.10M-$30.00M
Capital expenditure$2.66M$2.19M$1.20M$2.37M$3.44M$1.32M$1.72M$3.77M
Free cash flow-$27.97M$126.92M-$60.24M-$36.65M-$69.75M-$59.65M$868.38M-$33.77M
Investing cash flow-$442.41M-$122.56M-$93.74M$34.01M-$289.62M-$422.01M-$184.36M$267.71M
Financing cash flow-$73.24M$211.88M$6.40M$302.50M$15.22M$3.96M$9.41M$26.47M
Depreciation & amortization$16.82M$15.87M$15.41M$12.90M$11.11M$7.58M$7.22M$6.76M
Stock-based compensation$23.83M$23.29M$23.42M$18.52M$19.43M$18.54M$18.06M$17.24M

Free plan shows the latest 8 periods; Pro shows all 59 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.